BROSSARD, Quebec, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces the engagement of Investor Brand Network (“IBN”) to provide corporate communication and awareness solutions to the Corporation.

DIAGNOS Announces the Engagement of IBN

DIAGNOS, a leading company known for its innovative solutions, has recently made a significant announcement regarding its partnership with Investor Brand Network (IBN). This collaboration is expected to enhance DIAGNOS's market presence and drive awareness of its groundbreaking products and services. The company recognizes the importance of strategic partnerships in navigating the complexities of the modern business environment, particularly in the healthcare and technology sectors where competition is fierce.

Through this engagement, DIAGNOS aims to leverage IBN’s extensive network in the investment community to bolster its visibility and attract a broader audience. IBN is celebrated for its ability to connect dynamic companies with a diverse array of investors and consumers, maximizing outreach through effective marketing strategies. This partnership embodies DIAGNOS's commitment to growth and innovation, as it seeks to establish itself as a leader in its field.

DIAGNOS has developed a suite of cutting-edge technologies, particularly in artificial intelligence, which is reshaping the diagnostic landscape. The alignment with IBN will provide resources and expertise that facilitate further advancements in its product offerings, particularly in terms of marketing and investor relations. By enhancing communication strategies and media exposure, DIAGNOS is poised to reach pivotal growth milestones.

The health tech industry is rapidly evolving, and DIAGNOS is at the forefront of this transformation. With IBN's support, DIAGNOS will work to inform potential investors about its vision and the substantial impact its technologies could have on patient care and diagnostics. This proactive approach is designed to foster investor interest and trust in the company’s long-term goals and innovations.

As part of their partnership, IBN will help streamline the dissemination of information regarding DIAGNOS's upcoming projects, financial results, and key developments. By ensuring that relevant stakeholders are well-informed, DIAGNOS aims to build a strong, transparent relationship with its investing community, enhancing overall corporate governance through clear, consistent communication.

In summary, the engagement with IBN marks an exciting new chapter for DIAGNOS. This strategic collaboration is not only aimed at increasing shareholder value but also reflects the company's strategic planning in anticipation of future challenges and opportunities within the healthcare technology landscape. DIAGNOS is eager to harness this partnership to drive innovation, while IBN is committed to supporting DIAGNOS's journey towards achieving its ambitious objectives.